Endocrine aspects of acute and prolonged critical illness
- 1 January 2006
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Endocrinology & Metabolism
- Vol. 2 (1) , 20-31
Abstract
Critical illness is characterized by striking alterations in the hypothalamic-anterior-pituitary-peripheral-hormone axes, the severity of which is associated with a high risk of morbidity and mortality. Most attempts to correct hormone balance have been shown ineffective or even harmful because of a lack of pathophysiologic insight. There is a biphasic (neuro)endocrine response to critical illness. The acute phase is characterized by an actively secreting pituitary, but the concentrations of most peripheral effector hormones are low, partly due to the development of target-organ resistance. In contrast, in prolonged critical illness, uniform (predominantly hypothalamic) suppression of the (neuro)endocrine axes contributes to the low serum levels of the respective target-organ hormones. The adaptations in the acute phase are considered to be beneficial for short-term survival. In the chronic phase, however, the observed (neuro)endocrine alterations appear to contribute to the general wasting syndrome. With the exception of intensive insulin therapy, and perhaps hydrocortisone administration for a subgroup of patients, no hormonal intervention has proven to beneficially affect outcome. The combined administration of hypothalamic releasing factors does, however, hold promise as a safe therapy to reverse the (neuro)endocrine and metabolic abnormalities of prolonged critical illness by concomitant reactivation of the different anterior-pituitary axes.Keywords
This publication has 68 references indexed in Scilit:
- Effect of intravenous corticosteroids on death within 14 days in 10 008 adults with clinically significant head injury (MRC CRASH trial): randomised placebo-controlled trialThe Lancet, 2004
- Is There Still a Place for Dopamine in the Modern Intensive Care Unit?Anesthesia & Analgesia, 2004
- A Novel in Vivo Rabbit Model of Hypercatabolic Critical Illness Reveals a Biphasic Neuroendocrine Stress ResponseEndocrinology, 2002
- Ghrelin is a growth-hormone-releasing acylated peptide from stomachNature, 1999
- Increased Mortality Associated with Growth Hormone Treatment in Critically Ill AdultsNew England Journal of Medicine, 1999
- GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptorsAmerican Journal of Physiology-Endocrinology and Metabolism, 1999
- Thrity-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patientsGrowth Hormone & IGF Research, 1998
- A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone ReleaseScience, 1996
- Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐IClinical Endocrinology, 1991
- On thein Vitroandin VivoActivity of a New Synthetic Hexapeptide that Acts on the Pituitary to Specifically Release Growth Hormone*Endocrinology, 1984